Additional file 8: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Additional file 5: of Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Inez Johanna (6468737)
Trudy Straetemans (6468743)
Sabine Heijhuurs (6468746)
Tineke Aarts-Riemens (6468752)
Håkan Norell (6468755)
Laura Bongiovanni (662151)
Alain de Bruin (103917)
Zsolt Sebestyen (6468758)
Jürgen Kuball (6468761)

March 2019

Figure S3. In vivo efficacy profile of TEG001 in PD-X model of primary blast in NSG-SGM3 mice. (A) S...

Additional file 2: of Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Hang-Ping Yao (5452772)
Liang Feng (1634440)
Sreedhar Suthe (6468314)
Ling-Hui Chen (189004)
Tian-Hao Weng (5452778)
Chen-Yu Hu (4640824)
Eun Jun (6468317)
Zhi-Gang Wu (5452766)
Wei-Lin Wang (784760)
Song Kim (3503126)
Xiang-Min Tong (6468320)
Ming-Hai Wang (307679)

March 2019

Tables S1. Pathological and Biological Features of Primary PDAC Cell Lines from Patient-Derived Xeno...

Additional file 7: Figure S5. of Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

Jessalyn Ubellacker (3816346)
Marie-Therese Haider (3816340)
Molly DeCristo (3816343)
Gloria Allocca (3816352)
Nicola Brown (2269657)
Daniel Silver (2802739)
Ingunn Holen (3637012)
Sandra McAllister (3816349)

March 2017

a Growth kinetics of tumors after injecting host nude mice subcutaneously with admixtures of MDA-MB-...

Additional file 9: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S9. Potency of KRA-533 in genetically engineered LSL-KRASG12D LKB1fl/fl (KL) mice. (A) and (B...

Additional file 7: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S7. Determination of single dose maximum tolerated dose (MTD). (A) Nu/Nu nude mice were treat...

Additional file 1: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S1. KRA-533 inhibits proliferation of NSCLC cells. (A) A549, H157, Calu-1 and H292 cells were...

Additional file 6: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S6. Silencing of mutant KRAS reduced sensitivity of cells to KRA-533. (A) KRAS shRNA plasmids...

Additional file 2: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S2. KRA-533 induces caspase 3 activation and reduces mitochondrial membrane potential in NSCL...

Additional file 4: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S4. The autophagy inhibitor chloroquine blocks KRA-533-induced autophagy in NSCLC cells. A549...

Additional file 12: of Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway

Yanxia Jin (110467)
Qian Yang (300330)
Li Liang (365079)
Lu Ding (475637)
Yuxing Liang (5990960)
Dongdong Zhang (644246)
Balu Wu (5990963)
Tian Yang (318007)
Hailing Liu (2473138)
Tingting Huang (496866)
Hui Shen (66625)
Honglei Tu (5990966)
Yunbao Pan (286272)
Yongchang Wei (3778939)
Yi Yang (116183)
Fuling Zhou (286273)

November 2018

Figure S8. The anti-leukaemic effects of CKI on B-NSG mice with Molm-13 GFP+ cell injections. (A) A ...

Additional file 3: Table S1. of ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells

Reshma Thamkachy (3767449)
Rohith Kumar (465288)
K. Rajasekharan (3767446)
Suparna Sengupta (465292)

March 2016

Acute toxicity studies of DAT1. Swiss Albino mice were divided into 6 groups of 6 mice each and were...

Additional file 5: of The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway

Juri Ogishima (2902466)
Ayumi Taguchi (456506)
Akira Kawata (2902465)
Kei Kawana (162627)
Mitsuyo Yoshida (2902470)
Yuki Yoshimatsu (6039449)
Masakazu Sato (2902467)
Hiroe Nakamura (2902471)
Yoshiko Kawata (6039452)
Akira Nishijima (6039455)
Asaha Fujimoto (2902469)
Kensuke Tomio (456505)
Katsuyuki Adachi (528194)
Takeshi Nagamatsu (456511)
Katsutoshi Oda (162567)
Tohru Kiyono (334826)
Yutaka Osuga (456513)
Tomoyuki Fujii (276627)

December 2018

Figure S2. GFP-positive cancer cells in ID8 and ID8-KRAS cells in vivo. Mice were i.p. injected with...

Additional file 5: of MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer

Yoshimi Greer (6374504)
Samuel Gilbert (6374507)
Brunilde Gril (202357)
Rajesh Narwal (4425985)
Danielle Peacock Brooks (6374510)
David Tice (3173028)
Patricia Steeg (6374513)
Stanley Lipkowitz (253942)

February 2019

Histology analysis of extra MFP tumor developed in later stage in a mouse treated with MEDI3039. (A)...

Supplementary Figure S6 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Catherine Lee (16494521)
Ziyue Karen Jiang (16494524)
Simon Planken (16494527)
Lisa K. Manzuk (16494530)
Roberto Ortiz (16494533)
Michael Hall (16494536)
Kavon Noorbehesht (16494539)
Sripad Ram (15011832)
Timothy Affolter (16494542)
Gabriel E. Troche (16494545)
Nathan T. Ihle (16494548)
Theodore Johnson (16494551)
Youngwook Ahn (16494554)
Manfred Kraus (16494557)
Anand Giddabasappa (16494560)

July 2023

Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A...

Additional file 4: of Dihomo-γ-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase

Yi Xu (131145)
Xiaoyu Yang (547580)
Di Gao (501357)
Liu Yang (23752)
Keith Miskimins (5022932)
Steven Qian (5022929)

December 2018

Table S3. Two factor experiment table of the additive effect from D5D-KD/DGLA along with 5-FU’s on H...

Additional file 5: of Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Inez Johanna (6468737)
Trudy Straetemans (6468743)
Sabine Heijhuurs (6468746)
Tineke Aarts-Riemens (6468752)
Håkan Norell (6468755)
Laura Bongiovanni (662151)
Alain de Bruin (103917)
Zsolt Sebestyen (6468758)
Jürgen Kuball (6468761)

March 2019

Figure S3. In vivo efficacy profile of TEG001 in PD-X model of primary blast in NSG-SGM3 mice. (A) S...

Additional file 2: of Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Hang-Ping Yao (5452772)
Liang Feng (1634440)
Sreedhar Suthe (6468314)
Ling-Hui Chen (189004)
Tian-Hao Weng (5452778)
Chen-Yu Hu (4640824)
Eun Jun (6468317)
Zhi-Gang Wu (5452766)
Wei-Lin Wang (784760)
Song Kim (3503126)
Xiang-Min Tong (6468320)
Ming-Hai Wang (307679)

March 2019

Tables S1. Pathological and Biological Features of Primary PDAC Cell Lines from Patient-Derived Xeno...

Additional file 7: Figure S5. of Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

Jessalyn Ubellacker (3816346)
Marie-Therese Haider (3816340)
Molly DeCristo (3816343)
Gloria Allocca (3816352)
Nicola Brown (2269657)
Daniel Silver (2802739)
Ingunn Holen (3637012)
Sandra McAllister (3816349)

March 2017

a Growth kinetics of tumors after injecting host nude mice subcutaneously with admixtures of MDA-MB-...

Additional file 9: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S9. Potency of KRA-533 in genetically engineered LSL-KRASG12D LKB1fl/fl (KL) mice. (A) and (B...

Additional file 7: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S7. Determination of single dose maximum tolerated dose (MTD). (A) Nu/Nu nude mice were treat...

Additional file 1: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S1. KRA-533 inhibits proliferation of NSCLC cells. (A) A549, H157, Calu-1 and H292 cells were...

Additional file 6: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S6. Silencing of mutant KRAS reduced sensitivity of cells to KRA-533. (A) KRAS shRNA plasmids...

Additional file 2: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S2. KRA-533 induces caspase 3 activation and reduces mitochondrial membrane potential in NSCL...

Additional file 4: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Ke Xu (134879)
Dongkyoo Park (6578639)
Andrew Magis (227914)
Jun Zhang (48506)
Wei Zhou (24328)
Gabriel Sica (3458090)
Suresh Ramalingam (3458087)
Walter Curran (6578642)
Xingming Deng (239735)

April 2019

Figure S4. The autophagy inhibitor chloroquine blocks KRA-533-induced autophagy in NSCLC cells. A549...

Additional file 12: of Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway

Yanxia Jin (110467)
Qian Yang (300330)
Li Liang (365079)
Lu Ding (475637)
Yuxing Liang (5990960)
Dongdong Zhang (644246)
Balu Wu (5990963)
Tian Yang (318007)
Hailing Liu (2473138)
Tingting Huang (496866)
Hui Shen (66625)
Honglei Tu (5990966)
Yunbao Pan (286272)
Yongchang Wei (3778939)
Yi Yang (116183)
Fuling Zhou (286273)

November 2018

Figure S8. The anti-leukaemic effects of CKI on B-NSG mice with Molm-13 GFP+ cell injections. (A) A ...

Additional file 3: Table S1. of ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells

Reshma Thamkachy (3767449)
Rohith Kumar (465288)
K. Rajasekharan (3767446)
Suparna Sengupta (465292)

March 2016

Acute toxicity studies of DAT1. Swiss Albino mice were divided into 6 groups of 6 mice each and were...

Additional file 5: of The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway

Juri Ogishima (2902466)
Ayumi Taguchi (456506)
Akira Kawata (2902465)
Kei Kawana (162627)
Mitsuyo Yoshida (2902470)
Yuki Yoshimatsu (6039449)
Masakazu Sato (2902467)
Hiroe Nakamura (2902471)
Yoshiko Kawata (6039452)
Akira Nishijima (6039455)
Asaha Fujimoto (2902469)
Kensuke Tomio (456505)
Katsuyuki Adachi (528194)
Takeshi Nagamatsu (456511)
Katsutoshi Oda (162567)
Tohru Kiyono (334826)
Yutaka Osuga (456513)
Tomoyuki Fujii (276627)

December 2018

Figure S2. GFP-positive cancer cells in ID8 and ID8-KRAS cells in vivo. Mice were i.p. injected with...

Additional file 5: of MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer

Yoshimi Greer (6374504)
Samuel Gilbert (6374507)
Brunilde Gril (202357)
Rajesh Narwal (4425985)
Danielle Peacock Brooks (6374510)
David Tice (3173028)
Patricia Steeg (6374513)
Stanley Lipkowitz (253942)

February 2019

Histology analysis of extra MFP tumor developed in later stage in a mouse treated with MEDI3039. (A)...

Supplementary Figure S6 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Catherine Lee (16494521)
Ziyue Karen Jiang (16494524)
Simon Planken (16494527)
Lisa K. Manzuk (16494530)
Roberto Ortiz (16494533)
Michael Hall (16494536)
Kavon Noorbehesht (16494539)
Sripad Ram (15011832)
Timothy Affolter (16494542)
Gabriel E. Troche (16494545)
Nathan T. Ihle (16494548)
Theodore Johnson (16494551)
Youngwook Ahn (16494554)
Manfred Kraus (16494557)
Anand Giddabasappa (16494560)

July 2023

Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A...

Additional file 4: of Dihomo-γ-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase

Yi Xu (131145)
Xiaoyu Yang (547580)
Di Gao (501357)
Liu Yang (23752)
Keith Miskimins (5022932)
Steven Qian (5022929)

December 2018

Table S3. Two factor experiment table of the additive effect from D5D-KD/DGLA along with 5-FU’s on H...

Additional file 5: of Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells

Inez Johanna (6468737)
Trudy Straetemans (6468743)
Sabine Heijhuurs (6468746)
Tineke Aarts-Riemens (6468752)
Håkan Norell (6468755)
Laura Bongiovanni (662151)
Alain de Bruin (103917)
Zsolt Sebestyen (6468758)
Jürgen Kuball (6468761)

March 2019

Figure S3. In vivo efficacy profile of TEG001 in PD-X model of primary blast in NSG-SGM3 mice. (A) S...

Additional file 2: of Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Hang-Ping Yao (5452772)
Liang Feng (1634440)
Sreedhar Suthe (6468314)
Ling-Hui Chen (189004)
Tian-Hao Weng (5452778)
Chen-Yu Hu (4640824)
Eun Jun (6468317)
Zhi-Gang Wu (5452766)
Wei-Lin Wang (784760)
Song Kim (3503126)
Xiang-Min Tong (6468320)
Ming-Hai Wang (307679)

March 2019

Tables S1. Pathological and Biological Features of Primary PDAC Cell Lines from Patient-Derived Xeno...

Additional file 7: Figure S5. of Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

Jessalyn Ubellacker (3816346)
Marie-Therese Haider (3816340)
Molly DeCristo (3816343)
Gloria Allocca (3816352)
Nicola Brown (2269657)
Daniel Silver (2802739)
Ingunn Holen (3637012)
Sandra McAllister (3816349)

March 2017

a Growth kinetics of tumors after injecting host nude mice subcutaneously with admixtures of MDA-MB-...

Additional file 8: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Abstract

Extracted data

Additional file 8: of Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Abstract

Extracted data

Related items

Related items